Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | FNTA | P49354 | 2/20 | 0.59 |
| ▸ | FNTB | P49356 | 2/20 | 0.59 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788625 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL7217205 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL10937525 | 0.98 | ALDH1A1 (0.71) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL15228335 | 0.98 | ALDH1A1 (0.71) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL8662149 | 0.85 | ALDH1A1 (0.79) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| Geranyl Acetate SCHEMBL56914 | 0.85 | ALDH1A1 (1.00) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL7220410 | 0.85 | ALDH1A1 (0.79) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| Geranyl Acetate SCHEMBL1869319 | 0.85 | ALDH1A1 (1.00) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL28538300 | 0.85 | ALDH1A1 (0.79) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL8662151 | 0.85 | ALDH1A1 (0.79) | ALDH1A1ALOX15FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6600062-B2 | Enantioselectivity; epoxidizing and hydrolyzing the geranyloxy compound | DSM CATALYTICA PHARMACEUTICALS, INC. | 2003-07-29 | — | — | US | claimed |
| US-20020095061-A1 | Preparation of chiral 6,7-dihydroxy geranyloxy compounds | DSM CATALYTICA PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | claimed |
| US-6600062-B2 | Enantioselectivity; epoxidizing and hydrolyzing the geranyloxy compound | DSM CATALYTICA PHARMACEUTICALS, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020095061-A1 | Preparation of chiral 6,7-dihydroxy geranyloxy compounds | DSM CATALYTICA PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095061-A1 | Preparation of chiral 6,7-dihydroxy geranyloxy compounds | EPHX2, DHCR7, GGPS1 | ALDH1A1 180/4885ALOX15 157/4885FNTA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.